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Neuropsychiatric symptoms, previously denominated as behavioural and psychological symptoms of dementia, are common
features of Alzheimer’s disease (AD) and are one of the major risk factors for institutionalization. At present, the role of the
apolipoprotein E (APOE) gene in the development of neuropsychiatric symptoms in AD patients is unclear. In this paper, we
summarized the ﬁndings of the studies of neuropsychiatric symptoms and neuropsychiatric syndromes/endophenotypes in AD
in relation to APOE genotypes, with special attention to the possible underlying mechanisms. While some studies failed to ﬁnd
a signiﬁcant association between APOE and neuropsychiatric symptoms in late-onset AD, other studies reported a signiﬁcant
association between the APOE ε4 allele and an increase in agitation/aggression,hallucinations, delusions, and late-life depression
or anxiety. Furthermore, some negative studies that focused on the distribution of APOE genotypes between AD patients
with or without neuropsychiatric symptoms further emphasized the importance of subgrouping neuropsychiatric symptoms in
distinct neuropsychiatric syndromes. Explanations for the variable ﬁndings in the existing studies included diﬀerences in patient
populations, diﬀerences in the assessment of neuropsychiatric symptomatology, and possible lack of statistical power to detect
associationsin the negative studies.
1.Introduction
Dementia and age-related cognitive disorders are reaching
epidemic proportions, given the signiﬁcant increase in the
aging population. Alzheimer’s disease (AD), the most preva-
lent form of dementia [1], is a complex brain disorder that
has eﬀects on multiple cerebral systems, and characterized
by relatively slow but progressive neurodegeneration and
impairment in cognition, behavior, and functionality. Accu-
rate AD epidemiological data have been recently released
for the USA. The 2010 ﬁgures suggested that 5.3 million
Americans have AD [2], with >26 million patients with
AD worldwide, and an expected increase to more than 106
million by 2050 [3]. Neuropsychiatric symptoms, previously
denominated as behavioral and psychological symptoms of
dementia, are common features of AD [4, 5] and are one of
themajorriskfactorsforinstitutionalization[6]asw ellasfor
increasing costs both in USA and Western countries [7, 8].
Neuropsychiatric symptoms in AD include psychosis (delu-
sions and hallucinations) as well as aﬀective and behavioral
changes suchasdepressive mood, anxiety, irritability/lability,
apathy, euphoria, disinhibition, agitation/aggression, aber-
rant motor activities, sleep disturbance, and eating disorder
[9]. Neuropsychiatric symptoms associated with AD tend
to follow a trajectory of increasing severity over time, a
f e a t u r et h e yh a v ei nc o m m o nw i t hc o g n i t i v ea n df u n c t i o n a l
decline. Neuropsychiatric symptoms may be associated to
AD irrespective of cognitive impairment severity and may2 International Journal of Alzheimer’s Disease
be the presenting complaint or may emerge in the course
of the disease being important cause of a more rapid
cognitive decline [9]. It has been estimated that up to 80%
of patients with AD showed neuropsychiatric symptoms in
the history of the disease [9, 10]. Recently, the Behavioural
Subgroup of the European Alzheimer’s Disease Consortium
has performed a factor analysis of the neuropsychiatric
inventory (NPI) [11] in a homogeneous sample of patients
with AD, analyzing the largest AD population ever stud-
ied for this purpose [5]. The Behavioural Subgroup of
the European Alzheimer’s Disease Consortium identiﬁed 4
separateneuropsychiatricsyndromes:hyperactive,psychotic,
aﬀective, and apathetic [5], providing also evidence of the
relative consistency of neuropsychiatric syndromes across
dementia subtypes, age and gender [12], and stressing the
importance of thinking about neuropsychiatric syndromes
instead of separate symptoms in AD patients.
The majority of AD cases are sporadic (i.e., without
an apparent familial patterns of inheritance) compared
with fewer than 5% of cases that are caused by autosomal
dominantinheritanceofmutationsinpresenilin1,presenilin
2, or amyloid precursor protein [13]. Several genes have
been identiﬁed as possible risk factors for the development
of sporadic late-onset AD, particularly the gene dose of
apolipoprotein E (APOE) ε4 alleles [13]. In fact, the APOE
gene is the only globally valid genetic determinant of
sporadic AD to have been unambiguously identiﬁed in 15
years of intensive research [14]. However, as with other
multifactorial diseases, this systematic inability to detect new
genetic determinants has prompted more comprehensive
investigations using genome-wide association studies. Three
large genome-wide association studies in this ﬁeld were
performed and reported that the clusterin (CLU), phosphat-
idylinositol binding clathrin assembly protein (PICALM),
complement component (3b/4b) receptor 1 (CR1), bridging
integrator 1 (BIN1), and exocyst complex component 3-
like 2 (EXOC3L2) loci were associated with AD [15–17], in
addition to the established APOE relationship. The genetic
origin of the three common variants of the human APOE,
known as E2, E3, and E4, was understood in 1981 [18], and
since the mid of the 80s these are probably the most studied
protein variants in human races. A further study in 1982
proposed a nomenclature for these protein isoforms, to be
identiﬁed as E2, E3, and E4 [19]. These important ﬁndings
have led several researchers to the identiﬁcation of the APOE
encoding gene, that was recognized in 1982 [20], localized
on chromosome 19 at locus q13.31 [21], and deﬁnitively
sequenced [22]. Three years later, also the DNA encoding
these isoforms was deﬁnitively sequenced [23] and named
as ε2, ε3, and ε4. The important implications of this study
are the demonstration that these common gene variants
were generated by the two single-nucleotide polymorphisms
rs429358and rs7412inexon4oftheAPOEgene(AF261279)
and that these three allelic forms of the APOE gene are
indeed diﬀerent haplotypes of the APOE gene, generated by
the combination of the allele of these two single-nucleotide
polymorphisms at the APOE locus [13].
Therefore, risk for late-onset AD is known to be associ-
ated with polymorphisms of the APOE gene; people with an
ε4 allele have an increased risk of both familial and sporadic
forms, accounting for 20–50% of the attributable risk [13].
Nonetheless, APOE is neither necessary nor suﬃcient to
c a u s eA D ,a n dt h i si st h em a i nr e a s o nw h yA P O Ei sc l a s s i ﬁ e d
as a risk factor for AD and not a causative one. Although
this is currently a nonmodiﬁable risk factor, it has potential
for modifying the impact of other factors, in particular
vascularandlifestyle-related factors [24],implyingthatsome
interventions may perhaps best be restricted to people at
genetic risk. At present, the role of the APOE polymorphism
in the development of neuropsychiatric symptoms [25–
27] or neuropsychiatric syndromes/endophenotypes in AD
patients is unclear [28–30]. It has been suggested that
neuropsychiatric symptoms in AD may be inﬂuenced by
the APOE polymorphism in various case-control studies
[25, 26, 28, 29], but a recent longitudinal report showed a
substantial lack of association between the APOE ε4 allele
and neuropsychiatric symptoms in AD after correction for
multiple testing [27].
In this paper, we summarized the ﬁndings of the studies
of neuropsychiatric symptoms and neuropsychiatric syn-
dromes/endophenotypes in AD in relation to APOE geno-
typesfromthe English literaturepublished beforeSeptember
2010. We reviewed clinical and epidemiological studies from
the international literature, including both cross-sectional
and longitudinal studies that involved subjects aged 65 years
and older. We searched through the PubMed database of
NCBI (available at http://www.ncbi.nlm.nih.gov/)b ya u t h o r
and the following keywords: neuropsychiatric symptoms,
neuropsychiatric syndromes, neuropsychiatric endopheno-
types, apolipoprotein E, APOE, dementia, Alzheimer’s dis-
ease, late-life depression, late-life anxiety, aﬀective syn-
dromes, apathy, apathetic syndrome in dementia, agita-
tion, aggressiveness, hyperactive syndrome in dementia,
psychosis, psychotic syndrome in dementia, and behavioral
and psychological symptoms of dementia. Special attention
was paid to the possible mechanisms linked to the devel-
opment of neuropsychiatric symptoms and neuropsychiatric
syndromes/endophenotypes in AD in relation to APOE
genotypes.
2.APOE Genotypesand Affective
Syndromes/Endophenotypesin AD:
Late-LifeDepression and Anxiety
In adults older than 65 years, late-life depression refers to
depressive syndromes encompassing both late-onset cases as
well as early-onset cases that recur or continue into later
years of life [31, 32]. Late-life depressive syndromes often
arise in the context of medical and neurological disorders
[33]. The prevalence of major depressive disorder is about
17% in patients with AD [34] and is even higher in those
with subcortical dementias [31, 32]. Furthermore, emerging
research implicates also a consistent reciprocal relationship
between late life anxiety and cognition [35, 36]. In fact, anx-
iety disorders are the most common psychiatric diagnoses inInternational Journal of Alzheimer’s Disease 3
late life with an estimated lifetime prevalence of 15.3% in
older adults, surpassing population estimates for depressive
disorders [37], and severe cognitive impairment [38]. There
is evidenceof more prevalent anxiety in cognitivelyimpaired
older adults, elevated anxiety related to poorer cognitive
performance, and more severe anxiety symptoms predicting
future cognitive decline [35].
Early studies examining the relationship between APOE
genotypes and depression showed that the APOE ε4 allele
may be a risk factor for depressive symptoms in patients
with AD and dementia [39–41], and other investigators have
demonstratedcombinedrisksofdevelopingADamongthose
with late-life depression and APOE ε4 allele in nondemented
geriatric populations [42–45]( Table 1). These ﬁndings were
conﬁrmed in two very recent longitudinal population-based
studies [46, 47]. A recent study suggested that depression
and APOE ε4 genotype may be higher in women with AD
but not in men [48]. Consistent with these previous studies
demonstrating a relationship between APOE genotype and
depression in AD [29–41, 48], a recent report found that
depressed AD patients had a signiﬁcantly higher frequency
of APOE ε4 allele than nondepressed AD patients [49]. Also
in this study the association between APOE genotype and
depressioninADwasprimarily seeninwomenand notmen,
so conforming the results of a study showing an increased
rate ofthe APOEε4 genotypeinlate-onset depressed women
with AD relative to men [43]. Finally, in a very recent
study, when AD patients were subdivided according to the
European Alzheimer’s Disease Consortium classiﬁcation of
neuropsychiatric syndromes, in APO ε4-carriers there was
an increased risk of aﬀective syndrome (i.e., AD patients
with the NPI symptoms depression and anxiety) [30]. These
results on increased risk of an aﬀective syndrome in AD
patientsAPOEε4-carriers conﬁrmed recentﬁndings indicat-
ing that neuropsychiatric symptoms in AD are not purely
an epiphenomenon of cognitive impairment but could be
attributedtospeciﬁcbiologicalbraindysfunction, suggesting
the presence of speciﬁc AD endophenotypes [28, 29, 50–52].
Despitetheseﬁndings supporting anassociationbetween
APOE and depression, several other published studies have
not supported the notion that APOE ε4 genotype inﬂuences
depression in AD [25, 58, 66–69, 71], also when speciﬁc AD
endophenotypes were considered [28, 29]( Table 1). Other
reports suggested that in AD the APOE ε4 allele may be
protective against depression [80]o rt h a tA P O Eε2-carriers
may be at higher risk of depressive symptoms [53–55].
In addition, others have shown trends toward association
between APOE genotype and depression but have rendered
conclusions of no relationship [60, 77]. One possible expla-
nation for these contrasting ﬁndings may be the diﬀerent
sample size, with several studies including few depressed AD
patients [60, 67, 69], thus resulting in a diﬀerent power to
detect group diﬀerences. Also varying schemes for diagnos-
ing depression in AD may be a source of variability [25, 68,
71]. Another factor may be that the use of limited screening
measures for determining depression could be leading to
poorer diagnostic accuracy and thus diﬀerent prevalence
ratesof depressioninAD (range 11–50%)[25, 49, 60]. Thus,
the bulk of published studies reporting a lack of association
between APOE ε4 allele and depression in AD have suﬀered
from small sample sizes, low reported prevalence rates for
depression, very brief inventories of depressive symptoms,
and/or low diagnostic rigor in the determination of the
presence or absence of a Diagnostic and Statistical Manual
of Mental Disorders-based diagnosis of depression.
Anxietyismostcommonamong oldersubjectswith mild
cognitive impairment [81] and AD patients with a younger
age at onset (under age 65) [82]. APOE e4 allele is a risk
factor for developing AD at an earlier age [83]a n dm i g h t
contribute to this eﬀect [84]. Interestingly, APOE-null mice
carrying the human ε4 transgene had higher anxiety ratings
than those expressing either wild-type murine APOE or
the human ε3[ 73]. Very recently, these ﬁndings were also
conﬁrmed in female APOE TR mice expressing APOE under
control of the mouse APOE promoter. APOE4 mice showed
decreased activity levels and higher measures of anxiety
than mice expressing APOE2 or APOE3 across all ages
[85]. Notwithstanding the higher prevalence and symptom
expression of anxiety disorders in late life, not all measures
of neuropsychiatric symptoms in dementia reported in the
literature include an assessment of anxiety [82]. Two studies
using longitudinal assessments with the NPI found no asso-
ciation with anxiety [25, 65], and no association was found
when assessed by the Behavioural Pathology in Alzheimer’s
Disease Rating Scale (BEHAVE-AD) in a cross-sectional
study design [69]( Table 1). Consistent with the mouse
studies [73, 85], APOE also has isoform-dependent eﬀects
on measures of anxiety in probable AD patients [73]. In
particular, male ε4/ε4subjectshad higheranxietyscoresthan
gender-matched ε3/ε3 subjects. In males, but not in females,
subjects with ε4/ε4 had also higher anxiety scores than those
with ε3/ε4[ 73], suggesting that APOE3 can antagonize the
eﬀects of APOE4 on measures of anxiety in males but not
in females. The anxiety scores did not correlate with the
Mini-Mental State Examination scores [73]. Pritchard and
colleagues did not support these ﬁndings using the same
methodsofanalysis [27].However,theyfoundanassociation
with the APOEε3/ε4 genotype, but not with the APOE ε4/ε4
genotype or the e4 allele [27], so conﬁrming a previous
study in which anxiety appeared more frequently in APOE
ε3/ε4 demented patients, although this diﬀerence was not
statistically signiﬁcant [56]. Finally, when AD patients were
subdivided according to the European Alzheimer’s Disease
Consortium classiﬁcation of neuropsychiatric syndromes,
for the aﬀective syndrome (i.e., AD patients with the NPI
symptoms depression and anxiety), these previous ﬁndings
in AD and demented patients [27, 73, 74]w e r ec o n ﬁ r m e d
suggesting that the presence of an APOE ε4 allele may be a
risk factor also for anxiety symptoms [56].
3.APOE andApathyinAD
Apathy has been increasingly recognized as a distinct psy-
chiatric syndrome, and deﬁned as a lack of motivation, evi-
denced by diminished goal-directed overt behavior, dimin-
ished goal-directed cognition, and diminished emotional4 International Journal of Alzheimer’s Disease
Table 1: Principal studies on the association of neuropsychiatric symptoms, endophenotypes, and syndromes with the apolipoprotein E
(APOE) polymorphism in Alzheimer’s disease (AD) patients.
Reference Study sample Cognitive and neuropsychiatric
assessment Principal results
Ramachandran
et al. [39]
46 AD patients;
135 controls,
restricted to APOE
ε3/3 and ε3/4 only
CDR, HAM-D, and SCID-DSM-III-R
Depression rating greater with APOE ε3/4 versus ε3/3
reference genotype. Psychosis greater with ε3/4 versus
ε3/3 reference genotype
Holmes et al.
[53–55]
164 AD patients
232 AD patients
210 AD patients
BDRS
CAMDEX and MOUSEPAD
APOE ε2 allele signiﬁcantly associated with depressive
symptoms. APOE ε2 allele signiﬁcantlyassociated also
with persecutory delusions
Cacabelos et al.
[40, 56]
207 demented
patients
MMSE, GDS, ADAS, BCRS, FAST,
BEHAVE-AD, HAM-D, HAM-A, and
SDASDS
Disorientation, agitation, and motor disorders were
slightly more frequent in demented patients with APOE
ε4/e4, while anxiety and sleep disorders appeared more
frequently in APOE ε3/ ε4. However, these diﬀerences
were not statistically signiﬁcant
Lehtovirta et al.
[57]
58 AD patients and
16 controls
MMSE, BCRS, and HAM-D; the presence
of rigidity, hypokinesia, tremor at rest,
orofacial dyskinesia, myoclonus,
hallucinations,delusions, and diﬀerent
k i n d so fp a r e s i sw a sr e c o r d e di nt h e
neurologic examination. The occurrence
of epileptic seizures, hallucinations, and
delusions was also inquired from the
caregivers
Cognitive and neuropsychiatric symptoms and signs
were not related to the APOE genotype
Murphy et al.
[41] 77 AD patients MMSE, TBDQ, and ADAS non-cog APOE ε4 allele associated with higher scores on TBDQ
Cantillon et al.
[58] 162 AD patients MMSE and CSDD The APOE e4 allele frequency was not increased in the
late-onset depression group amongthese AD patients
Ballard et al. [80]5 1 A Dp a t i e n t s CAMCOG, CSDD, Burns symptom
checklist, and SCID-DSM-III-R
Protective eﬀect of APOE ε4 allele against depression.
APOE ε4-carriers more likely to have future psychotic
episode
Forsell et al.
[60, 61]
806 participants
aging 78 years and
over
MMSE and CPRS Depressed and nondepressed subjects had similar
APOE genotype distributions among the demented,
and amongthe nondemented, subjects. There was also
no statistical signiﬁcant diﬀerence in APOE genotype
between subjects with and without psychotic
symptoms, stratiﬁed by dementia diagnosis
668 participants
aging 75 years and
over
Dementia was diagnosed using the
DSM-III-R criteria Psychotic symptoms
were deﬁned according to DSM-IV
criteria
Lopez et al. [62] 194 AD patients MMSE. BRS-CERAD, and
semi-structured psychiatric interview
No evidence for an association of NPS with any speciﬁc
APOE genotype in probable AD patients
Lyketsos et al.
[63] 120 AD patients
Diagnoses for major and minor
depression according to DSM-IV, and
assessmentof delusions or hallucinations
according to DSM-IV glossary deﬁnitions
There was no association between APOE genotype and
the presence of NPS or the neuropsychiatric syndromes
examined. There was an interesting suggestion that the
e4 allele may be protective against the development of
major depression; however, this associationdid not
reach statistical signiﬁcance
Hirono et al.
[64, 65]
228 AD patients MMSE, BEHAVE-AD, and NPI The APOE ε4 allele had no eﬀect on the manifestation
of delusions, hallucinations,depression, or other NPS
in AD 175 AD patients MMSE, CDR, and the Japanese
version1of the NPI
Levy et al. [25] 605 AD patients MMSE and NPI
Among patients with comparable disease severity, the
APOE ε4 allele does not confer additional psychiatric
morbidity
Harwood et al.
[66] 501 AD patients
MMSE, HAM-D, and structured
interview for speciﬁc delusions and
hallucinations
Increased risk for psychosis with APOE ε4 allele
M¨ uller-Thomsen
et al. [48] 137 AD patients MMSE and MADRS Overrepresentation of the APOE ε4 allele in female AD
patientsInternational Journal of Alzheimer’s Disease 5
Table 1: Continued.
Reference Study sample Cognitive and neuropsychiatric
assessment Principal results
Liu et al. [67] 149 AD patients CASI, CDR, HAM-D, and
SCID-DSM-III-R
No evidence of an association between depression in
AD patients and presence or absence of the APOE ε4o r
ε2 allele
Scarmeas et al.
[68] 87 AD patients MMSE, CUSPAD, BDRS, and
SCID-DSM-III-R
APOE ε4 alleles associated with risk for incident
delusions. APOE ε4/ε4 predicted protective eﬀect
against hallucinations
Gabryelewicz
et al. [69] 139 AD patients MMSE, GDS, and BEHAVE-AD The APOE e4 allele had no eﬀect on the behavioural
changes in AD
Sweet et al. [70] 316 AD patients MMSE, BRS-CERAD, and
SCID-DSM-III-R
There was no signiﬁcant associationof APOE genotype
with time to psychosis onset and no signiﬁcant
interaction of this genotypes with time to psychosis
onset
Craig et al.
[26, 71]
400 AD patients
404 AD patients
NPI with caregiver distress
MMSE and NPI with caregiver distress
Increase in agitation/aggressionin patients with the
APOE ε4 allele, while APOE genotype created no
additional risk for depressive symptoms in AD
Chang et al. [72] 135 AD patients CASI, CDR, and SCID-DSM-III-R APOE ε4 signiﬁcantly associated with hallucinations
and delusions
Robertson et al.
[73] 125 AD patients CSDD and NPI Greater level of anxiety in APOE ε4/ε4v e r s u sε3ε/3
bearers in both genders and versus ε3/ε4i nm a l e so n l y
Borroni et al. [28]232 AD patients
By Principal Component Analysis of NPI
symptoms, four endophenotypes were
identiﬁed, these were termed “psychosis,”
“moods,” “apathy,” and “frontal”
APOE genotype did not correlate with any
neuropsychiatric endophenotype
Hollingworth
et al. [29] 1,120 AD patients
By Principal Component Analysis of NPI
symptoms, four interpretable
components were identiﬁed: behavioral
dyscontrol (euphoria, disinhibition,
aberrant motor behavior, and sleep and
appetite disturbances), psychosis
(delusions and hallucinations),mood
(depression, anxiety, and apathy), and
agitation (aggressionand irritability)
None of the neuropsychiatric endophenotypes
identiﬁed were associated with age at assessment,years
of education, or number of APOE ε4 alleles
Monastero et al.
[74] 197 AD patients MMSE and NPI
The presence of apathy was signiﬁcantlyassociated with
the APOE ε4 allele independently from age, education,
sex, and duration of disease
Spalletta et al.
[59] 171 AD patients MMSE and NPI
The associationbetween NEUROPSYCHIATRIC
SYMPTOMS and APOE ε4 allele in AD was conﬁrmed
for delusions only
Pritchard et al.
[27] 388 AD patients MMSE and NPI
Protective eﬀect of the APOE ε3/ε4g e n o t y p et h a tw a s
signiﬁcantlyassociated with hallucinations symptoms.
APOE ε3/ε4 genotype is signiﬁcantly associated with
anxiety
van der Flier et al.
[75] 110 AD patients MMSE and NPI
Delusions and agitation/aggressionwere more common
and severer amonghomozygous APOE ε4 carriers than
amongheterozygous or APOE-ε4-negative patients
Zdanys et al. [76] 266 AD patients MMSE, ADL, IADL, and NPI
APOE ε4 was signiﬁcantly associated with psychotic
s y m p t o m s ,a d j u s t i n gf o ra g e ,s e x ,e d u c a t i o n ,a n d
MMSE score
Delano-Wood
et al. [49] 323 AD patients MMSE and SCID-DSM-III-R
Higher prevalence rate of the APOE ε4g e n o t y p ei nt h e
depressed group compared to the nondepressed AD
patients. This eﬀect was primarily accounted for by
women6 International Journal of Alzheimer’s Disease
Table 1: Continued.
Reference Study sample Cognitive and neuropsychiatric
assessment Principal results
Chopra et al. [77]
175 cognitively
impaired subjects,
of which 92 AD and
80 MCI patients
MMSE, GDS-15, and NPI
The diﬀerence in the proportion of participant
reporting “low energy” at GDS-15 between the three
APOE ε4 allele frequency groups approached statistical
signiﬁcance
Del Prete et al.
[78] 53 AD patients MMSE and NPI
Patients with APOE 4 allele showed a wider range of
NEUROPSYCHIATRIC SYMPTOMS when compared
to noncarriers and higher scores for hallucinations and
aberrant motor behaviors. Over time, ε4 carriers
showed an increase/delayed onset in some symptoms
and a parallel decrease in others, while noncarriers
presented an undiﬀerentiated worsening of
symptomatology
Woods et al. [79] 36 demented
patients MMSE and mABRS
Patients with an APOE ε4 allele had a signiﬁcant
increase in their observed NEUROPSYCHIATRIC
SYMPTOMS,including restlessness and vocalizations,
compared to those who did not have an APOE ε4 allele
present
D’Onofrio et al.
[30]
201 AD patients and
121 controls
MMSE, ADL, IADL, CIRS, and
NPI. Furthermore, AD patients
with NEUROPSYCHIATRIC
SYMPTOMS were further
subdivided in four groups
according to the EADC
classiﬁcation of neuropsychiatric
syndromes in AD: hyperactive,
psychotic, aﬀective, and apathetic
No diﬀerence in the distribution of APOE genotypes
was found between AD patients with and without
NEUROPSYCHIATRIC SYMPTOMS. In AD patients
APOE ε4-carriers, there was an increased risk of
aﬀective and apathetic syndromes
CDR: Clinical Dementia Rating scale; HAM-D: Hamilton rating scale for depression; SCID-DSM-III-R: Structured Clinical Interview for Diagnostic and
StatisticalManual of Mental Disorders-III-revised; BDRS: BlessedDementia Rating Scale;CAMDEX: The Cambridge examinationfor mentaldisorders of the
elderly; MOUSEPAD: Manchester and Oxford universities scale for the psychopathological assessmentof dementia; MMSE: Mini Mental State Examination;
GDS: Global Deterioration Scale; ADAS: Alzheimer’s Disease Assessment Scale; BCRS: Brief Cognitive Rating Scale; FAST: Functional Assessment Stages;
BEHAVE-AD: Behavioural Pathology in Alzheimer’s Disease Rating Scale; HAM-A: Hamilton rating scale for anxiety; SDASDS: Senile Dementia-Associated
Sleep Disorders Scale; TBDQ: time-based behavioural disturbance questionnaire (does patient display any of following symptoms in 1 month prior to
assessment (combativeness, agitation, wandering, incoherent speech, hallucinations, confusion, and disorientation); ADAS non-cog: Alzheimer’s disease
assessment scale noncognitive subscale; CSDD: Cornell Scale for Depression in Dementia; CAMCOG: Cambridge assessment for mental disorders in the
elderly; CPRS: Comprehensive Psychopathological Rating Scale; BRS-CERAD: Behavior Rating Scale for dementia of the Consortium to Establish a Registry
for Alzheimer’s Disease; DSM-IV: Diagnostic and StatisticalManual of Mental Disorders-IV; NPI: NeuropsychiatryInventory; MADRS: Montgomery-Asberg
Depression rating Scale; CASI: Cognitive AbilitiesScreening Instrument; CUSPAD: Colombia University Scale for Psychopathology in AD; ADL: activities of
daily living; IADL: instrumental activities of daily living; GDS-15: 15-item Geriatric Depression Scale; MCI: mild cognitive impairment; mABRS: modiﬁed
Agitated Behavior Rating Scale; CIRS: Cumulative Illness Rating Scale; EADC: European Alzheimer’s Disease Consortium.
concomitants of goal-directed behavior [86, 87]. To date,
there is no clear consensus on the deﬁnition of apathy,
and it is not included in the glossary of the Diagnostic
and Statistical Manual of Mental Disorders-lV [88]a n d
mentioned merely as a nonspeciﬁc symptom of several
disorders. Anhedonia or loss of interest or pleasure can be
used as a principal symptom to diagnose major depressive
disorder instead of or along with depressed mood. Because
other criteria for Diagnostic and Statistical Manual of
Mental Disorders-IV diagnosis of major depressive disorder
[88] such as fatigue, hypersomnia or insomnia, loss of
appetite, weight loss, and diminished ability to concentrate
are prevalent among demented patients, a demented patient
withapathy maybemisdiagnosed as havingmajor depressive
disorder even in the absence of dysphoria [89]. This diag-
nostic challenge stems from the apparent overlap between
apathy and depression [90]. Apathy has been reported to be
common in AD outpatients, and the reported prevalence for
apathyusing theNPIwasbetween32.1%and 93.2%[91,92].
Also the relationship between the APOE e4 allele and the
apathetic syndrome and/or the apathy symptom was studied
[28–30, 36–38, 70, 74, 75, 93], although it has not been as
thoroughly investigated as for depression or psychosis. In
a sample of 197 subjects with probable AD, the presence
of apathy was signiﬁcantly associated with the APOE e4
allele independently from age, education, sex, duration of
disease, Mini-Mental State Examination score, and other
neuropsychiatric symptoms [74]. Furthermore, the recent
results on an increased risk of the European Alzheimer’s Dis-
ease Consortium apathetic syndrome (i.e., NPI symptoms
apathy and eating abnormalities) in AD patients APOE ε4-
carriers [30] conﬁrmed these previous ﬁndings suggesting
a relationship between the APOE ε4 allele and apathy in
patients with AD [74], although other studies did not showInternational Journal of Alzheimer’s Disease 7
any correlation between apathy endophenotypes [28, 29]o r
NPI apathy symptom [75] and APOE genotypes (Table 1).
4.APOEand Psychotic Symptoms and
Syndromes/EndophenotypesinAD
Among neuropsychiatric symptoms in AD, major attention
has been dedicated to psychotic symptoms, that typically
consist of delusions and/or hallucinations [94]. The preva-
lence of psychosis is quite substantial, with estimates for
delusions in AD ranging from 9.3% to 63% (median 36%)
and estimates for hallucinations ranging from 4% to 41%
(median 18%) [95]. However, psychosis proved to be a
coherent grouping of psychiatric symptoms in AD in studies
using cluster and factor analysis [94, 96]. Therefore, it
has been reported that AD patients with psychosis (AD +
psychosis, AD + P) may be clinically diﬀerent from AD
[93, 94, 97]. Indeed, an increased familial risk for the
AD + P endophenotype has been observed [70], suggesting
heritability[88,98]andthusapossiblegeneticcomponentof
this clinical feature. In fact, genes that have been implicated
in psychosis of AD include those for dopamine-3 and
serotonin-2A receptors [98]. Major attention has been ded-
icated to psychotic episodes in relation to APOE genotypes,
and a number of investigations have examined whether the
APOE ε4 allele might contribute to the AD + P endophe-
notype [98]. Among initial studies conducted in unrelated
AD + P and AD without psychosis subjects, one large [66]
and two smaller studies [39, 80] have found an association of
APOE ε4 allele and the AD + P endophenotype. However,
most successive reports have found no association of the
APOE e4 allele with AD + P [25, 27, 40, 56, 61, 99, 100]
(Table 1), suggesting that it may be necessary to operate a
distinction among diﬀerent psychotic symptoms in AD in
relation to APOE polymorphism. However, also association
studies with hallucinations have been contradictory, with
two copies of ε4 being reported as protective [68], ε4
being associated with increased risk [72], and hallucinations
appeared to increase with more ε4 alleles [101]o ra l s o ,i na
small longitudinal study, to decrease 1 year after diagnosis
in AD patients with one ε4 allele [78]. The association of
hallucinationsin ADwith thee3/ε4genotype[27]also added
further inconsistencies to reported ﬁndings. Hallucinations
are sometimes incorporated into a measure of psychosis,
but also these studies have again been inconsistent, with
signiﬁcant associations being reported for the ε4 allele [66]
and for ε3/ε4v e r s u sε4/ε4 carriers [39]. Furthermore, when
the outcome was the presence of delusions in AD patients,
in a longitudinal study, one ε4 allele carried 2.5-fold risk
whereas thepresence oftwo ε4alleles carried 5.6-foldrisk for
development of delusions during a 9.3-year followup [68].
These ﬁndings were conﬁrmed in other two longitudinal
studies in which the presence of the APOE ε4 allele carried a
3.4-fold risk for developing delusions [72] and the presence
of one e4 allele, 1 year after diagnosis, showed a moderate,
but signiﬁcant, increase in delusions [78]. Also in cross-
sectional studies, APOE ε4 allele possession was associated
with increased levelsof delusionswithin the last month from
the ﬁrst visit and with the presence of categorical delusions
at the early stage until the ﬁrst visit [59], delusions appeared
to increase with more ε4 alleles [101]a n dε4/ε4g e n o t y p e
[75], and ε4 was preferentially associated with delusions
also in a large sample of AD patients from the USA [76].
However, when AD patients were subdivided according to
the European Alzheimer’s Disease Consortium classiﬁcation
of neuropsychiatric syndromes, for psychotic syndrome,
including AD patients with delusions, hallucinations, and
night-time disturbances, no association was found between
APOE polymorphism and this neuropsychiatric syndrome
[30]. These ﬁndings were consistent with those of a larger
number of studies in which no association was found
between APOE genotypes and the psychotic endophenotype
[28, 29] or also single psychotic symptoms or measures
incorporatingthesesymptoms,thatis,hallucinations[26,57,
62–65, 69] and delusions [62, 65]( Table 1).
5.APOE,Agitation/Aggressiveness,
and Hyperactive
Syndrome/EndophenotypeinAD
Agitation/aggressiveness diﬀers from psychosis and depres-
sion of AD in that it may be conceptualized as a single
symptom or a symptom complex [94]. The prevalence of
agitation in dementia ranges from 20% to 60%, depending
on diagnostic deﬁnitions used and the population studied
[102]. A formalized deﬁnition of agitation was proposed as
“inappropriate verbal, vocal, or motor activity that is not
judged by an outside observer to be an obvious outcome of
the needs or confusion of the individual” [103]. Agitation/
aggressiveness in dementia often co-occurs with psychosis
and depression. There is substantial evidence that verbal agi-
tation is associated with depression, and there may be some
relationship to delusions [94, 104]. Psychosis, particularly
delusions, and depression occur with increased frequency
in aggressive patients and may be a causative factor [105].
Alsothesymptom complexagitation/aggressiveness has been
linkedtoAPOEgenotypes.Agitationanddisorientationwere
more common in demented patients ε4/ε4 carriers, whereas
anxiety and sleep disorders were more common in ε3/ε4
carriers, although these diﬀerences were not statistically
signiﬁcant [40, 56]. In another report, it was noted that
t h ep r e s e n c eo ft h eε4 allele was associated with increased
combativeness, agitation, wandering, and confusion [41].
These ﬁndings were conﬁrmed in two other recent studies
in which the APOE ε4 allele has been associated with agi-
tation/aggressiveness using the Neuropsychiatric Inventory
Caregiver Distress Scale (NPI-D) [26, 75], and in a recent
report in which the presence of the APOE e4+ genotype
increased the risk for agitated behaviour, including rest-
lessness and vocalizations, in nursing home residents with
dementia [79]( Table 1). However, when AD patients were
subdivided according to the European Alzheimer’s Disease
Consortium classiﬁcation of neuropsychiatric syndromes,
for hyperactive syndrome, including AD patients with
agitation, euphoria, disinhibition, irritability, and aberrant
motor behaviour, no association was found between APOE8 International Journal of Alzheimer’s Disease
genotypes and this neuropsychiatric syndrome, as also was
found for psychotic syndrome [30]. These ﬁndings on
the European Alzheimer’s Disease Consortium hyperactive
syndrome were similar to previous negative results in en-
dophenotype [29], single symptom approach [25, 65], and
in a study evaluating risk for incident neuropsychiatric
symptoms in a prospectively followed cohort [68]( Table 1).
6.Mechanisms Linking Neuropsychiatric
Symptoms and Syndromes/Endophenotypes
withAPOEGenotypesinAD
ThepresentreviewedevidenceonapossibleroleoftheAPOE
polymorphism on the development of neuropsychiatric
symptoms in AD patients conﬁrmed that genetic factors
may account for some of the neuropsychiatric heterogeneity
associated with AD [106, 107]. The role of APOE in
AD-related depression is still controversial, and additional
research is needed [108]. However, recent evidence has been
accumulatingtosuggestthatAPOEmaybelinkedtovascular
risk factors in late life and, in turn, may be associated with
depression. Indeed, it has been posited that the ε4 allele may
be a predisposing genetic marker for ischemic cerebrovas-
cular disease [109] given its association with hyperlipidemia
[110],atherosclerosis[111],myocardialinfarction [112],and
subcortical white matter lesion pathology [113]. Some late-
life depressive syndromes might predispose, precipitate, or
perpetuatebycerebrovasculardisease,theso-called“vascular
depression” hypothesis [114, 115]. In fact, a history of stroke
was associated with a 3-4-fold increased risk of apathy and
depression in AD [116], and cerebrovascular disease has
previously been linked to depression in several studies of
individuals with dementia [117]. In addition, the APOE ε4
allele may increase the odds that older depressed patients
develop mild cognitive impairment [118]. Finally, it has
been proposed that, for those carrying a copy of the ε4
allele, the destructive eﬀect of subtle, underlying vascular
risk factors, may be enhanced [113]. Furthermore, the APOE
ε4 allele appears to be less eﬃcient than other isoforms in
inducing cholesterol transport [119], which may have an
important role in maintaining the integrity of membranes,
and in synaptic plasticity. Thus, it appears that the APOE
ε4 allele is associated with impaired response to cerebral
damage and diminished capacity for neuronal repair [120,
121] and that this poorer neuronal reparative capacity may
be implicated in the development of cognitive decline and
depression in older adults with the APOE ε4 genotype.
Finally, for aﬀective syndromes and/or symptoms in AD,
also the mechanisms underlying the suggested association
between late-life anxiety and APOE in AD are, at present,
not completely understood [73, 84, 85]. Interestingly, higher
measures of anxiety were reported in male mice lacking
murine APOE (APOE−/−)t h a ni ns e x - m a t c h e dw i l d - t y p e
controls [73, 84]. There were isoform-dependent eﬀects of
APOE on measures of anxiety in male APOE−/− and APOE3
and APOE4 mice expressing human APOE in neurons under
control of the neuron-speciﬁc enolase (NSE) promoter or
in astrocytes under control of the glial ﬁbrillary acidic
protein (GFAP) promoter [73, 84]. APOE−/− and APOE4
male mice showed increased measures of anxiety, whereas
APOE3 mice behaved like wild-type controls [73, 84]. Very
recently, these ﬁndings were also conﬁrmed in female APOE
TR miceexpressing APOEundercontrolofthemouse APOE
promoter [85]. APOE4 mice showed decreased activity levels
and higher measures of anxiety than mice expressing APOE2
or APOE3 across all ages [85].
The association of cerebrovascular disease with apathy
may reﬂect stroke-related damage to areas of the prefrontal
cortex or related neural pathways, involved in the planning
and execution of goal-directed behavior [122]. In fact,
apathy is associated with frontal and subcortical pathology
[123, 124], and more severe apathy has been related with
a severe impairment of frontal executive functions [125].
Functional imaging studies revealed that apathy in AD is
related to dysfunction of the right temporoparietal and
anterior cingulate cortices [122, 123], regions involved in
frontal-subcortical networks. A recent neuropathological
study reported a signiﬁcant relationship between chronic
apathy and anterior cingulated cortex tangle pathology
[124].ApatheticpatientswithADtreatedwithcholinesterase
inhibitors showed a signiﬁcant reduction in apathy [126].
This is probably related to loss of nucleus basalis of Meynert
cholinergic inputtoprefrontal and subcorticalregions [122].
Interestingly, the APOE ε4 allele has been associated with
a severe loss of cholinergic activity in the frontal cortex
[127] and with enhanced β-amyloid deposition in thefrontal
region of nondemented presenile subjects [128].
Although the ε4 allele has been shown to promote
the neuropathological features of AD, including β-amyloid
deposition [129, 130] and neuroﬁbrillary tangle formation
[129, 130], attempts to relate these features to psychotic
symptoms in AD have yielded conﬂicting results [131,
132]. Therefore, neuropsychiatric symptomatology could
be associated with more severe neuropathological changes,
although there is no clear consensus on this. Furthermore,
the ε4 allele has been associated with more profound
deﬁcits in cholinergic neurons, in particular in the frontal
cortex [127] and medial temporal lobe [133], whereas the
development of neuropsychiatric symptoms in AD appears
toberelatedtospeciﬁcneurotransmitterimbalances,notably
acetylcholine [134]. Psychotic manifestations in AD have
been associated with pathology in the temporal lobe and
hippocampus [131, 135] .O n es i n g l ep h o t o ne m i s s i o nc o m -
puted tomography study has suggested that delusions in
AD may be associated with hypoperfusion in the temporal
lobes [136], and some [137]b u tn o ta l l[ 138]f u n c t i o n a l
imaging studies have shown that AD patients who carry the
ε4 allele have reduced temporal lobe function. The structural
magnetic resonance imaging literature is more uniﬁed in
showing greater medial temporal lobe atrophy in association
with the ε4a l l e l ei nA D[ 139–141]. It is conceivable
that the detected association between APOE genotype and
psychotic symptom, particularly delusions, might reﬂect
neuropathology more heavily concentrated in the temporal
lobe. Finally, also the mechanisms of the possible association
between APOE and aggressive/agitated behaviour in AD are
unclear. APOE is associated with more rapid progression asInternational Journal of Alzheimer’s Disease 9
measured by single photon emission computed tomography
and higher tangle burden in the brain [130, 138, 142,
143]. The accepted spread of neuropathological damage
seen in AD, from the hippocampus to frontal-temporal-
parietal regions, may encourage the development of those
behavioural symptoms that not only localize regionally
within the brain but are dependent on progressive neuronal
loss and amyloid deposition away from the mesial temporal
lobe. Frontal involvement is the best neuroanatomical corre-
late for aggression and agitation with secondary disruption
of the serotonergic and dopaminergic systems [144–147].
High agitation scores correlate with bilateral orbitofrontal
and left anterior cingulatedtangle burden [144]a n dwi t hl e f t
fronto-temporal hypoperfusion on single photon emission
computed tomography scanning [145].
7.Conclusions
Environmental factors that have been associated with late-
onsetADincludedepressivesyndromes, variousvascularrisk
factors, level of education, head trauma, and dietary factors.
This complexity may help explain their high prevalence
from an evolutionary perspective, but the etiologic com-
plexity makes identiﬁcation of disease-related genes much
more diﬃcult [148]. The “endophenotype” approach is
an alternative method for measuring phenotypic variation
that may facilitate the identiﬁcation of susceptibility genes
for complexly inherited traits [148]. The association of
the APOE genotypes with neuropsychiatric symptoms or
neuropsychiatric syndromes and endophenotypes in AD
appeared to be still unclear. Neuropsychiatric symptoms in
diﬀerent times could coexist in a single patient showing
a very complex psychological proﬁle. The discrepancy in
dementia syndromes between the occurrence of neuropsy-
chiatric symptoms from rather linear cognitive decline
implies independent pathophysiological pathways between
these symptoms. In particular, contrasting ﬁndings existed
on the possible association between aﬀective symptoms or
syndromes in AD and APOE genotypes, with studies with
measures of late-life depressive syndromes and symptoms
more frequent than studies that focused on late-life anxiety.
At present, there is only limited evidence of an increased risk
of apathy or agitated behaviour linked to the presence of
APOE ε4 allele in AD patients. Furthermore, some studies
have found an association between APOE ε4 allele and
the AD plus psychosis endophenotype, with several studies
suggesting a possible role of this polymorphism when the
outcome was the presence of delusions in AD patients rather
than of hallucinations. The fact that some studies assessing
neuropsychiatric symptoms in relation to APOE status often
analyzed the dichotomized APOE ε4 status rather than
the number of APOE e4 alleles may partially account for
these contrasting ﬁndings, suggesting a methodological limit
for the correct evaluation of predisposing factors and the
pathogeneticbasisofneuropsychiatricsymptomsinAD.Dis-
crepant ﬁndings may be due also to other factors including
small sample sizes, diﬀerences in sample compositions (e.g.,
general “dementia” groups versus strictly diagnosed patients
with “probable AD,” with some of the studies including
patients with Lewy body disease), the use of very brief, wide-
ranging, or unstructured psychopathology inventories, and
possible lack of statistical power to detect associations in
thenegative studies.Furthermor e ,s o m en e g a t i v es t u d i e st h a t
focused on the distribution of APOE genotypes between AD
patients with or without neuropsychiatric symptoms further
emphasized the importance of subgrouping these symp-
toms in distinct neuropsychiatric syndromes, suggesting
also genetic basis for individual neuropsychiatric symptoms.
In addition, many of the above studies did not control
for potential confounding variables. Most important, many
reviewed studies were cross-sectional, whereas it would be of
paramount importance to evaluate the risk for incident neu-
ropsychiatricsymptomsinrelationtotheAPOEgenotypesin
prospectively followed cohorts of AD patients. In fact, cross-
sectional studies have limitations in interpreting the causal
relationship between APOE and neuropsychiatric symptoms
or neuropsychiatric syndromes/endophenotypes. Further
longitudinal studies on larger sample of patients are needed
to clarify the possible role of this gene in neuropsychiatric
symptoms or neuropsychiatric syndromes/endophenotypes
in AD.
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